Publications by authors named "K Raun"
Objective: Co-treatment with long acting PYY and the GLP-1 receptor agonists has potential as an efficient obesity treatment. This study investigates whether the mechanisms behind additive reduction of food intake and weight loss depends on complementary effects in brain areas regulating food intake and if restoration of leptin sensitivity is involved.
Methods: Diet-induced obese (DIO) mice were co-treated with PYY(3-36) and exendin-4 (Ex4, GLP-1R agonist) for 14 days using minipumps.
Evaluation of weight loss drugs is usually performed in diet-induced obese mice housed at ∼22°C. This is a cold stress that increases energy expenditure by ∼35% compared to thermoneutrality (∼30°C), which may overestimate drug-induced weight loss. We investigated five anti-obesity mechanisms that have been in clinical development, comparing weight loss in mice housed at 22°C vs.
View Article and Find Full Text PDFAmylin, a member of the calcitonin family, acts via amylin receptors in the hindbrain and hypothalamus to suppress appetite. Native ligands of these receptors are peptides with short half-lives. Conjugating fatty acids to these peptides can increase their half-lives.
View Article and Find Full Text PDFArticle Synopsis
- GIPR and GLP-1R receptor agonists improve blood sugar control and aid in weight loss, and both types of receptors are present in the brain region that regulates these processes.
- Recent research has highlighted that receptor activity-modifying proteins (RAMPs) influence how these receptors function, particularly in relation to the glucagon receptor family, which includes GIPR and GLP-1R.
- A study using mice lacking RAMP1 and RAMP3 showed that while these receptors alone had minimal effect on weight loss, their combined use significantly decreased body weight, particularly in the RAMP-deficient mice, suggesting RAMPs are important for effective receptor function.